Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Peter Salmon | M | 84 |
Cell Analysis Ltd.
Cell Analysis Ltd. BiotechnologyHealth Technology Cell Analysis Ltd. develops applications and solutions based on cell analysis. It offers food authenticity, agricultural breed genetics, and diagnostic products for human genetic disorders. The company was founded in 1999 and is headquartered in Slough, the United Kingdom. | - |
Robert Anthony | M | - |
Cell Analysis Ltd.
Cell Analysis Ltd. BiotechnologyHealth Technology Cell Analysis Ltd. develops applications and solutions based on cell analysis. It offers food authenticity, agricultural breed genetics, and diagnostic products for human genetic disorders. The company was founded in 1999 and is headquartered in Slough, the United Kingdom. | 25 anni |
Nicola Kerslake | F | - |
Cell Analysis Ltd.
Cell Analysis Ltd. BiotechnologyHealth Technology Cell Analysis Ltd. develops applications and solutions based on cell analysis. It offers food authenticity, agricultural breed genetics, and diagnostic products for human genetic disorders. The company was founded in 1999 and is headquartered in Slough, the United Kingdom. | - |
Neal Bradshaw | M | - |
Cell Analysis Ltd.
Cell Analysis Ltd. BiotechnologyHealth Technology Cell Analysis Ltd. develops applications and solutions based on cell analysis. It offers food authenticity, agricultural breed genetics, and diagnostic products for human genetic disorders. The company was founded in 1999 and is headquartered in Slough, the United Kingdom. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Shalom Hirschman | M | 85 |
Advanced Viral Research Corp.
Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | - |
Stephen M. Elliston | M | 73 |
Advanced Viral Research Corp.
Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | - |
Elma Hawkins | M | 67 |
Advanced Viral Research Corp.
Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | - |
Charles H. Moore | M | 94 |
Advanced Viral Research Corp.
Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | - |
Eli Wilner | M | 68 |
Advanced Viral Research Corp.
Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | 8 anni |
David Seligman | M | - |
Advanced Viral Research Corp.
Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | 4 anni |
Nancy J. van Sant | F | - |
Advanced Viral Research Corp.
Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | 4 anni |
Irach Taraporewala | M | 68 |
Advanced Viral Research Corp.
Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | 6 anni |
Angelo S. Botter | M | 76 |
Advanced Viral Research Corp.
Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | 3 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 9 | 69.23% |
Regno Unito | 4 | 30.77% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Roy S. Walzer
- Contatti personali